FDA Decisions Put Johnson & Johnson's Growth And Valuation In Focus [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
FDA grants Priority Review for Johnson & Johnson's IMAAVY (nipocalimab) in warm autoimmune hemolytic anemia, the first therapy in this rare blood disorder to receive that designation. FDA approves a supplemental New Drug Application for CAPLYTA (lumateperone) to include prevention of schizophrenia relapse based on long term data. Both decisions expand Johnson & Johnson's (NYSE:JNJ) mix of late stage and approved therapies in immunology and neuropsychiatry. For investors watching large healthcare names, these twin FDA decisions highlight where Johnson & Johnson is putting its weight. IMAAVY targets warm autoimmune hemolytic anemia, a rare and life threatening condition that currently has no FDA approved therapies. CAPLYTA sits in the neuropsychiatric segment, where long term treatment needs are significant. Together, they broaden J&J's exposure beyond its more familiar pharmaceutical and medtech lines. Looking ahead, the key variables for NYSE:JNJ will be the outcome of the IM
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- ACROBiosystems and SeromYx Systems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies [Yahoo! Finance]Yahoo! Finance
- FDA tests out ‘real-time' clinical trials; AbbVie closes in on a KRAS biotech [Yahoo! Finance]Yahoo! Finance
- Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact [Yahoo! Finance]Yahoo! Finance
- ‘American industry is winning': White House touts factory boom — how investors can ride the reshoring wave [Yahoo! Finance]Yahoo! Finance
- Poolbeg eyes transformative summer with POLB 001 data in prospect [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 4/14/26 - Beat
JNJ
Sec Filings
- 4/28/26 - Form 8-K
- 4/27/26 - Form 4
- 4/27/26 - Form 4
- JNJ's page on the SEC website